{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:25:58Z","timestamp":1789521958581,"version":"build-2803163510"},"reference-count":32,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,6,1]]},"abstract":"<jats:p>Objective. To evaluate an approach to the diagnosis and treatment of maple syrup disease (MSD).<\/jats:p>\n                  <jats:p>Methods. Family histories and molecular testing for the Y393N mutation of the E1\u03b1 subunit of the branched-chain \u03b1-ketoacid dehydrogenase allow us to identify infants who were at high risk for MSD. Amino acid concentrations were measured in blood specimens from these at-risk infants between 12 and 24 hours of age. An additional 18 infants with MSD were diagnosed between 4 and 16 days of age because of metabolic illness.<\/jats:p>\n                  <jats:p>A treatment protocol for MSD was designed to 1) inhibit endogenous protein catabolism, 2) sustain protein synthesis, 3) prevent deficiencies of essential amino acids, and 4) maintain normal serum osmolarity. Our protocol emphasizes the enhancement of protein anabolism and dietary correction of imbalances in plasma amino acids rather than removal of leucine by dialysis or hemofiltration. During acute illnesses, the rate of decrease of the plasma leucine level was monitored as an index of net protein synthesis. The treatment protocol for acute illnesses included the use of mannitol, furosemide, and hypertonic saline to maintain or reestablish normal serum sodium and extracellular osmolarity and thereby prevent or reverse life-threatening cerebral edema. Similar principles were followed for both sick and well outpatient management, especially during the first year, when careful matching of branched-chain amino acid intake with rapidly changing growth rates was necessary. Branched-chain ketoacid excretion was monitored frequently at home and branched-chain amino acid levels were measured within the time of a routine clinic visit, allowing immediate diagnosis and treatment of metabolic derangements.<\/jats:p>\n                  <jats:p>Results. 1) Eighteen neonates with MSD were identified in the high-risk group (n = 39) between 12 and 24 hours of age using amino acid analysis of plasma or whole blood collected on filter paper. The molar ratio of leucine to alanine in plasma ranged from 1.3 to 12.4, compared with a control range of 0.12 to 0.53. None of the infants identified before 3 days of age and managed by our treatment protocol became ill during the neonatal period, and 16 of the 18 were managed without hospitalization.<\/jats:p>\n                  <jats:p>2) Using our treatment protocol, 18 additional infants who were biochemically intoxicated at the time of diagnosis recovered rapidly. In all infants, plasma leucine levels decreased to &amp;lt;400 \u03bcmol\/L between 2 to 4 days after diagnosis. Rates of decrease of the plasma leucine level using a combination of enteral and parenteral nutrition were consistently higher than those reported for dialysis or hemoperfusion. Prevention of acute isoleucine, valine, and other plasma amino acid deficiencies by appropriate supplements allowed a sustained decrease of plasma leucine levels to the therapeutic range of 100 to 300 \u03bcmol\/L, at which point dietary leucine was introduced.<\/jats:p>\n                  <jats:p>3) Follow-up of the 36 infants over &amp;gt;219 patient years showed that, although common infections frequently cause loss of metabolic control, the overall rate of hospitalization after the neonatal period was only 0.56 days per patient per year of follow-up, and developmental outcomes were uniformly good. Four patients developed life-threatening cerebral edema as a consequence of metabolic intoxication induced by infection, but all recovered. These 4 patients each showed evidence that acutely decreased serum sodium concentration and decreased serum osmolarity were associated with rapid progression of cerebral edema during their acute illnesses.<\/jats:p>\n                  <jats:p>Conclusions. Classical MSD can be managed to allow a benign neonatal course, normal growth and development, and low hospitalization rates. However, neurologic function may deteriorate rapidly at any age because of metabolic intoxication provoked by common infections and injuries. Effective management of the complex pathophysiology of this biochemical disorder requires integrated management of general medical care and nutrition, as well as control of several variables that influence endogenous protein anabolism and catabolism, plasma amino acid concentrations, and serum osmolarity.<\/jats:p>","DOI":"10.1542\/peds.109.6.999","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T20:17:55Z","timestamp":1092428275000},"page":"999-1008","source":"Crossref","is-referenced-by-count":243,"title":["Diagnosis and Treatment of Maple Syrup Disease: A Study of 36 Patients"],"prefix":"10.1542","volume":"109","author":[{"given":"D. Holmes","family":"Morton","sequence":"first","affiliation":[{"name":"Clinic for Special Children, Strasburg Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Strauss","sequence":"additional","affiliation":[{"name":"Clinic for Special Children, Strasburg Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Clinic for Special Children, Strasburg Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik G.","family":"Puffenberger","sequence":"additional","affiliation":[{"name":"Clinic for Special Children, Strasburg Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard I.","family":"Kelley","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute and Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2002,6,1]]},"reference":[{"key":"2021121006225047100_R1","doi-asserted-by":"crossref","unstructured":"Mitsubuchi H, Matsuda I, Nobukuni Y, et al. Gene analysis of Mennonite maple syrup urine disease kindred using primer-specified restriction map modification. J Inherit Metab Dis.1992;15:181\u2013187","DOI":"10.1007\/BF01799628"},{"key":"2021121006225047100_R2","doi-asserted-by":"crossref","unstructured":"Korein J, Sansaricq C, Kalmijn M, Honig J, Lange B. Maple syrup urine disease: clinical, EEG, and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity. Int J Neurosci.1994;79:21\u201345","DOI":"10.3109\/00207459408986065"},{"key":"2021121006225047100_R3","doi-asserted-by":"crossref","unstructured":"Chuang JL, Davie JR, Chinsky JM, Wynn RM, Cox RP, Chuang DT. Molecular and biochemical basis of intermediate maple syrup urine disease. Occurrence of homozygous G245R and F364C mutations at the E1 alpha locus of Hispanic-Mexican patients. J Clin Invest.1995;95:954\u2013963","DOI":"10.1172\/JCI117804"},{"key":"2021121006225047100_R4","doi-asserted-by":"crossref","unstructured":"Berry GT, Heidenreich R, Kaplan P, et al. Branched-chain amino acid-free parenteral nutrition in the treatment of acute metabolic decompensation in patients with maple syrup urine disease. N Engl J Med.1991;324:175\u2013179","DOI":"10.1056\/NEJM199101173240307"},{"key":"2021121006225047100_R5","doi-asserted-by":"crossref","unstructured":"Thompson GN, Francis DE, Halliday D. Acute illness in maple syrup urine disease: dynamics of protein metabolism and implications for management. J Pediatr.1991;119:35\u201341","DOI":"10.1016\/S0022-3476(05)81035-2"},{"key":"2021121006225047100_R6","doi-asserted-by":"crossref","unstructured":"Riviello JJ Jr, Rezvani I, DiGeorge AM, Foley CM. Cerebral edema causing death in children with maple syrup urine disease. J Pediatr.1991;119:42\u201345","DOI":"10.1016\/S0022-3476(05)81036-4"},{"key":"2021121006225047100_R7","doi-asserted-by":"crossref","unstructured":"DiGeorge AM, Rezvani I, Garibaldi LR, Schwartz M. Prospective study of maple-syrup-urine disease for the first four days of life. N Engl J Med.1982;307:1492\u20131495","DOI":"10.1056\/NEJM198212093072405"},{"key":"2021121006225047100_R8","unstructured":"Shih VE. Laboratory Techniques for the Detection of Hereditary Metabolic Disorders. Cleveland, OH: CRC Press; 1973"},{"key":"2021121006225047100_R9","unstructured":"Fisher CW, Fisher CR, Chuang JL, Lau KS, Chuang DT, Cox RP. Occurrence of a 2-bp (AT) deletion allele and a nonsense (G-to-T) mutant allele at the E2 (DBT) locus of six patients with maple syrup urine disease: multiple-exon skipping as a secondary effect of the mutations. Am J Hum Genet.1993;52:414\u2013424"},{"key":"2021121006225047100_R10","doi-asserted-by":"crossref","unstructured":"Mortimore GE, Poso AR. Intracellular protein catabolism and its control during nutrient deprivation and supply. Annu Rev Nutr.1987;7:539\u2013564","DOI":"10.1146\/annurev.nu.07.070187.002543"},{"key":"2021121006225047100_R11","doi-asserted-by":"crossref","unstructured":"Ziegler TR, Benfell K, Smith RJ, et al. Safety and metabolic effects of L-glutamine administration in humans. JPEN J Parenter Enteral Nutr.1990;14:137S\u2013146S","DOI":"10.1177\/0148607190014004201"},{"key":"2021121006225047100_R12","doi-asserted-by":"crossref","unstructured":"Ziegler TR, Gatzen C, Wilmore DW. Strategies for attenuating protein-catabolic responses in the critically ill. Annu Rev Med.1994;45:459\u2013480","DOI":"10.1146\/annurev.med.45.1.459"},{"key":"2021121006225047100_R13","doi-asserted-by":"crossref","unstructured":"Naylor EW, Guthrie R. Newborn screening for maple syrup urine disease (branched-chain ketoaciduria). Pediatrics.1978;61:262\u2013266","DOI":"10.1542\/peds.61.2.262"},{"key":"2021121006225047100_R14","doi-asserted-by":"crossref","unstructured":"Chace DH, Hillman SL, Millington DS, Kahler SG, Roe CR, Naylor EW. Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectrometry. Clin Chem.1995;41:62\u201368","DOI":"10.1093\/clinchem\/41.1.62"},{"key":"2021121006225047100_R15","doi-asserted-by":"crossref","unstructured":"Seashore MR. Tandem spectrometry in newborn screening. Curr Opin Pediatr.1998;10:609\u2013614","DOI":"10.1097\/00008480-199810060-00013"},{"key":"2021121006225047100_R16","doi-asserted-by":"crossref","unstructured":"Leonard JV, Daish P, Naughten ER, Bartlett K. The management and long term outcome of organic acidaemias. J Inherit Metab Dis.1984;1:13\u201317","DOI":"10.1007\/BF03047367"},{"key":"2021121006225047100_R17","doi-asserted-by":"crossref","unstructured":"Naughten ER, Jenkins J, Francis DE, Leonard JV. Outcome of maple syrup urine disease. Arch Dis Child.1982;57:918\u2013921","DOI":"10.1136\/adc.57.12.918"},{"key":"2021121006225047100_R18","doi-asserted-by":"crossref","unstructured":"Kaplan P, Mazur A, Field M, et al. Intellectual outcome in children with maple syrup urine disease. J Pediatr.1991;119:46\u201350","DOI":"10.1016\/S0022-3476(05)81037-6"},{"key":"2021121006225047100_R19","doi-asserted-by":"crossref","unstructured":"Kroll M, Juhler M, Lindholm J. Hyponatraemia in acute brain disease. J Intern Med.1992;232:291\u2013297","DOI":"10.1111\/j.1365-2796.1992.tb00588.x"},{"key":"2021121006225047100_R20","doi-asserted-by":"crossref","unstructured":"Ganong CA, Kappy MS. Cerebral salt wasting in children. The need for recognition and treatment. Am J Dis Child.1993;147:167\u2013169","DOI":"10.1001\/archpedi.1993.02160260057022"},{"key":"2021121006225047100_R21","doi-asserted-by":"crossref","unstructured":"Harrison LI, Christensen HN. Simulation of differential effects on rates in membrane transport. J Theor Biol.1975;49:439\u2013459","DOI":"10.1016\/S0022-5193(75)80047-6"},{"key":"2021121006225047100_R22","doi-asserted-by":"crossref","unstructured":"Christensen HN. Interorgan amino acid nutrition. Physiol Rev.1982;62:1193\u20131233","DOI":"10.1152\/physrev.1982.62.4.1193"},{"key":"2021121006225047100_R23","doi-asserted-by":"crossref","unstructured":"Smith QR, Momma S, Aoyagi M, Rapoport SI. Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem.1987;49:1651\u20131658","DOI":"10.1111\/j.1471-4159.1987.tb01039.x"},{"key":"2021121006225047100_R24","unstructured":"DiLiberti JH, DiGeorge AM, Auerbach VH. Abnormal leucine\/isoleucine ratio and acrodermatitis enteropathica-like rash in maple syrup urine disease (MSUD) [abstract]. Pediatr Res.1973;7:382"},{"key":"2021121006225047100_R25","doi-asserted-by":"crossref","unstructured":"Northrup H, Sigman ES, Hebert AA. Exfoliative erythroderma resulting from inadequate intake of branched-chain amino acids in infants with maple syrup urine disease [letter]. Arch Dermatol.1993;129:384\u2013385","DOI":"10.1001\/archderm.129.3.384"},{"key":"2021121006225047100_R26","unstructured":"Polin RA, Fox WW. Fetal & Neonatal Physiology. Philadelphia, PA: WB Saunders; 1998"},{"key":"2021121006225047100_R27","unstructured":"Chuang DT, Shih VE. Disorders of branched chain amino acid and keto acid metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 1994:1281"},{"key":"2021121006225047100_R28","doi-asserted-by":"crossref","unstructured":"McKean CM, Boggs DE, Peterson NA. The influence of high phenylalanine and tyrosine on the concentrations of essential amino acids in brain. J Neurochem.1968;15:235\u2013241","DOI":"10.1111\/j.1471-4159.1968.tb06202.x"},{"key":"2021121006225047100_R29","doi-asserted-by":"crossref","unstructured":"Kamei A, Takashima S, Chan F, Becker LE. Abnormal dendritic development in maple syrup urine disease. Pediatr Neurol.1992;8:145\u2013147","DOI":"10.1016\/0887-8994(92)90038-Z"},{"key":"2021121006225047100_R30","doi-asserted-by":"crossref","unstructured":"Benitez-Bribiesca L, De la Rosa-Alvarez I, Mansilla-Olivares A. Dendritic spine pathology in infants with severe protein-calorie malnutrition. Pediatrics.1999;104(2). Available at: http:\/\/www.pediatrics.org\/cgi\/content\/full\/104\/2\/e21","DOI":"10.1542\/peds.104.2.e21"},{"key":"2021121006225047100_R31","doi-asserted-by":"crossref","unstructured":"Christensen HN. Hypothesis: where the depleted plasma amino acids go in phenylketonuria, and why. Perspect Biol Med.1987;30:186\u2013196","DOI":"10.1353\/pbm.1987.0034"},{"key":"2021121006225047100_R32","unstructured":"Martin JH. Neuroanatomy Text and Atlas. 2nd ed. Norwalk, CT: Appleton & Lange; 1996"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/6\/999\/995769\/pe0602000999.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/6\/999\/995769\/pe0602000999.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T09:29:45Z","timestamp":1639128585000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/109\/6\/999\/64139\/Diagnosis-and-Treatment-of-Maple-Syrup-Disease-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,1]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2002,6,1]]},"published-print":{"date-parts":[[2002,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.109.6.999","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6,1]]}}}